Evidence map›Paper›PMID 40820727›Full record

ArticleHaematologica2026

Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-

Mengge Gao, Kainan Zhang, Siqi Li, Huidong Guo, Yuqian Sun, Jun Kong, Tingting Han, Yingjun Chang, Xiaojun Huang, Xiaosu Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengge GaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Kainan ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Siqi LiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Huidong GuoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Yuqian SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Jun KongPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Tingting HanPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Yingjun ChangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China; Collaborative Innovation Center of Hematology, Peking University.
Xiaosu ZhaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029; Collaborative Innovation Center of Hematology, Peking University. zhao.xiaosu@outlook.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulocyte colony-stimulating factor (G-CSF) enhances acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT) by inducing T-cell tolerance and altering graft cell composition. Previous studies have shown that the number of mucosa-associated invariant T (MAIT) cells in G-CSF-induced graft was associated with a low incidence of gut aGVHD. However, the effect of G-CSF mobilization on MAIT cell and its role in MAIT-mediated protection against gut GVHD remain unclear. Here, using single-cell RNA sequencing, we found that the interaction of G-CSF with its receptor CSF3R enhances immunosuppression and tissue repair functions of MAIT cells, contributing to the anti-gut aGVHD effect. The chemokine receptor CXCR6 was identified as potentially crucial for recruiting these functional MAIT cells to gut tissues. Furthermore, we simulated the dynamic distribution of MAIT cells from donor G-CSF-mobilized peripheral blood stem cells (G-PBSC) grafts in recipient mouse, and further confirmed that the circulating MAIT cells migrated into gut tissue in a CXCR6-CXCL16-dependent manner. To further validate these findings, we developed a flow cytometry panel that effectively predicts the gut aGVHD occurrence following allo-HSCT by analyzing the frequency and functional markers of MAIT cells in G-PBSC. The predictive model shifts aGVHD prediction and intervention to the pre-transplant stage and offers a new strategy for the prevention and management of gut aGVHD in clinical practice.

Indexed as

Gastrointestinal DiseasesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMucosal-Associated Invariant T CellsSequence Analysis, RNASingle-Cell AnalysisAnimalsFemaleHumansMaleMiceMice, Inbred C57BLTissue DonorsTransplantation, Homologous

Identifiers

PMID40820727
PMCPMC12775736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.